menu
    • menu
    [{"orgOrder":0,"company":"UTC Therapeutics","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"UCMYM802","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"UTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UTC Therapeutics \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"UTC Therapeutics \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"UTC Therapeutics","sponsor":"The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"UTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UTC Therapeutics \/ The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"1","companyTruncated":"UTC Therapeutics \/ The First Affiliated Hospital of Zhengzhou University"}]

    Find Clinical Drug Pipeline Developments & Deals by UTC Therapeutics

    Menu

    UTC Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UTC Therapeutics

                            Singapore arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UTC Therapeutics

                            Singapore arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : The First Affiliated Hospital of Zhengzhou University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 26, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : The First Affiliated Hospital of Zhengzhou University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UTC Therapeutics

                            Singapore arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UTC Therapeutics

                            Singapore arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UCMYM802

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

                            Details : UCMYM802 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mesothelioma, Malignant.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 13, 2024

                            Lead Product(s) : UCMYM802

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth